Psikotrop İlaçların Ürolojik Acilleri ve Klinik Yönetimi: Priapizm ve Akut İdrar Retansiyonu

Authors

Kutay Topal
Murat Cengizhan Atik

Synopsis

Psychotropic drugs are widely used in the treatment of psychiatric disorders; however, serious urological side effects may occur due to the adrenergic, cholinergic, and dopaminergic mechanisms of these drugs. This chapter addresses two important urological emergencies: priapism and acute urinary retention (AUR). The pathophysiology, clinical features, diagnostic methods, and current treatment approaches of both conditions are presented in the light of the literature. Early recognition of these complications is of critical importance in preventing permanent damage.

References

Türkiye Psikiyatri Derneği. Antipsikotik tedavide yan etki yönetimi kılavuzu. Ankara: Türkiye Psikiyatri Derneği Yayınları; 2022.

Ehrt U, Czekaj LE, Eknes J, et al. Urinary incontinence in patients with schizophrenia. Acta Psychiatrica Scandinavica. 2011;124(3):214-222.

Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. International Clinical Psychopharmacology. 2011;26(3):130-140.

Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: pathogenesis, epidemiology, and management. Journal of Sexual Medicine. 2010;7(1):476-500.

Bird ST, Delaney JA, Brophy JM, et al. Antipsychotic drug use and the risk of acute urinary retention in patients with lower urinary tract symptoms. Canadian Medical Association Journal. 2016;188(9):E220-E226.

Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. Journal of Urology. 2003;170(4):1318-1324.

Thompson JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. Journal of Clinical Psychiatry. 1990;51(10):430-433.

Carneiro A, Wroclawski ML, Nahas WC, et al. Drug-induced priapism: a systematic review and meta-analysis. Journal of Sexual Medicine. 2020;17(7):1227-1239.

Akkuzu G, Taşdemir N. Psikiyatrik ilaçların ürolojik yan etkileri: bir gözden geçirme. Türk Psikiyatri Dergisi. 2018;29(3):195-203.

Becker AJ, Stief CG. Pathophysiology of priapism. European Urology Supplements. 2009;8(4):266-269.

Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. Journal of Sexual Medicine. 2010;7(1):524-540.

Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. European Urology. 2014;65(2):480-489.

Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta3-adrenoceptor agonist, in overactive bladder. European Urology. 2013;63(2):296-305.

McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. European Urology. 2004;45(3):325-332.

Published

November 17, 2026

License

License